Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-20), Jacobio Pharmaceuticals Group Co's 3-1 Month Momentum % is 17.46%.
Jacobio Pharmaceuticals Group Co (STU:77V) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Jacobio Pharmaceuticals Group Co 3-1 Month Momentum % Related Terms
STU:77V vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's 3-1 Month Momentum % falls into.
Jacobio Pharmaceuticals Group Co (STU:77V) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co (STU:77V) has a 3-1 Month Momentum % of 17.46% as of Sep. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #332 out of 1384 companies in the Biotechnology industry, placing it in the top 24%.
Is Jacobio Pharmaceuticals Group Co's 3-1 Month Momentum % too high?
Jacobio Pharmaceuticals Group Co's current 3-1 Month Momentum % is 17.46%. The Biotechnology industry median 3-1 Month Momentum % is 0.44. Jacobio Pharmaceuticals Group Co's value of 17.46% is 3868.2% above this industry median. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #332 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #332 out of 1384 companies for 3-1 Month Momentum %. This places Jacobio Pharmaceuticals Group Co in the top 24% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 0.44. Jacobio Pharmaceuticals Group Co's value of 17.46% is 3868.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.44, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobio Pharmaceuticals Group Co's current 3-1 Month Momentum % of 17.46% is 3868.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current 3-1 Month Momentum % is 17.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co (STU:77V) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.21, compared to a current price of €0.60 — trading 185.7% above its estimated fair value. The current 3-1 Month Momentum % is 17.46% and 3868.2% above the Biotechnology industry median of 0.44. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (STU:77V), the current 3-1 Month Momentum % is 17.46% as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (STU:77V) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of €0.60 is trading 185.7% above its estimated GF Value™ of €0.21.
GuruFocus considers Jacobio Pharmaceuticals Group Co to be Significantly Overvalued.
Key valuation signals for STU:77V:
3-1 Month Momentum %: 17.46%
GF Value™: €0.21 vs. price of €0.60 (185.7% above fair value)
Industry Position: 3868.2% above the Biotechnology median (#332 of 1384)
No single metric tells the full story. See the STU:77V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
26GF Score
Get the complete analysis for STU:77V
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:77V has been successfully added to your 
